Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice

We identified all patients with chronic lymphocytic leukemia at Mayo Clinic treated with ibrutinib outside the context of a clinical trial; timing and reasons for discontinuation were ascertained, as were symptoms, exam and radiographic findings, and laboratory changes following discontinuation. Of...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Leuk Lymphoma
المؤلفون الرئيسيون: Hampel, Paul J., Ding, Wei, Call, Timothy G., Rabe, Kari G., Kenderian, Saad S., Witzig, Thomas E., Muchtar, Eli, Leis, Jose F., Chanan-Khan, Asher A., Koehler, Amber B., Fonder, Amie L., Schwager, Susan M., Slager, Susan L., Shanafelt, Tait D., Kay, Neil E., Parikh, Sameer A.
التنسيق: Artigo
اللغة:Inglês
منشور في: 2019
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6813846/
https://ncbi.nlm.nih.gov/pubmed/31014142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2019.1602268
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة